Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class A

As of June 30, 2026, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H carries a market capitalization of 46.64B, placing it among publicly traded companies globally. Its enterprise value stands at 46.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H's next confirmed earnings release is scheduled for March 31, 2027.

As of June 30, 2026, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has 997.77M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H maintains a current ratio of 3.42, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 23, 2026, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H's stock has gained approximately 77.35% over the past 52 weeks. The 50-day moving average sits at 61.54, while the 200-day moving average is 52.77.

As of June 30, 2026, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H holds 1.16B in cash and equivalents against 801.52M in total debt, resulting in a net debt position of -725.56M. Total book value stands at 2.80B, with working capital of 1.39B providing operational flexibility.